Últimos Artículos de Lancet Diabetes & Endocrinology
- [Editorial] Out of touch medical care
- [Editorial] Innovation is key to transforming future obesity care
- [Comment] Endocrine–neuropsychological interplay underpinning maternal postpartum depression
- [Correspondence] High cost and poor availability of continuous glucose monitoring in low-income and middle-income countries
- [Correspondence] Diabetic foot ulcer prevention in Kuwait
- [Corrections] Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7
- [Comment] Obesity medications versus metabolic bariatric surgery: the debate goes on
- [Articles] 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study
- [Corrections] Correction to Lancet Diabetes Endocrinol 2016; 4: 850–61
- [Correspondence] Treatment duration for romosozumab – Authors' reply
- [Correspondence] Treatment duration for romosozumab
- [Comment] Early-stage type 1 diabetes: is there a role for lifestyle modifications?
- [In Focus] Ethical eating: food choices that make a difference
- [TimeCapsule] A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention
- [Articles] Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
- [Articles] Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
- [Comment] Cagrilintide–semaglutide: a new option for patients with type 2 diabetes
- [Corrections] Correction to Lancet Diabetes Endocrinol 2026; 14: 259–74
- [Editorial] Bearing metabolism in mind: towards integrated care
- [Correspondence] Genetics of pancreatic agenesis: a 21-year international cohort study